A5019038240- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Peptidase Inhibition and Analysis
- Parathyroid Disorders and Treatments
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Acute Myeloid Leukemia Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- T-cell and B-cell Immunology
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
- Eosinophilic Disorders and Syndromes
- Monoclonal and Polyclonal Antibodies Research
- Plant Virus Research Studies
- Immunotherapy and Immune Responses
- Chemokine receptors and signaling
- Cancer Mechanisms and Therapy
Universitätsklinikum Würzburg
2020-2025
University of Würzburg
2020-2021
New York University
2013
Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve prognosis patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin light chains are causal agents in ATTR AL amyloidosis. In these most frequent subtypes, cardiac involvement common organ manifestation. Because function frequently deteriorate over time, even under best...
Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis remains challenging, and prognosis very poor. were excluded from the pivotal trial leading to approval daratumumab in combination bortezomib-cyclophosphamide-dexamethasone. This retrospective, multicenter study evaluates addition first-line therapy newly diagnosed AL amyloidosis. In total, data 119 consecutive analyzed, 27 received an upfront treatment including daratumumab, 63 a bortezomib-based regimen without 8...
Abstract The definition of high‐risk (HR) multiple myeloma (MM) is still a matter debate. We prospectively evaluated the HR detection using FISH in combination with SKY92 gene expression profiling 258 MM patients (newly diagnosed [ND] MM: n = 109; relapsed/refractory [RR] 149). was significantly enriched RRMM (57/121, 47.1%) compared NDMM (17/95, 17.9%) ( p < 0.0001). showed shorter progression‐free survival (PFS) 0.0001) and overall (OS) than standard‐risk (SR). In NDMM, also indicated...
<title>Abstract</title> Extramedullary multiple myeloma (EMD) is associated with low response rates, short progression-free survival and poor prognosis. CAR T cells bispecific antibodies (bsABs) have shown efficacy in relapsed but it remains uncertain whether one cell redirection strategy should be preferred. We retrospectively analyzed 80 patients EMD not adjacent to the bone treated ide-cel, cilta-cel, teclistamab or talquetamab at three academic centers Germany. All were heavily...
Published experience with carfilzomib in patients relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy safety of containing therapy regimens EMD. We retrospectively analyzed 45 RRMM treated from June 2013 September 2019. median age at start was 64 (range 40–80) years. Twenty (44%) 25 (56%) had paraosseous manifestation EMD without adjacency bone, respectively. serological overall response rate (ORR) 59%....
Abstract Background Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due demyelination. Patients usually present confusion seizures. Late diagnosis lack adequate therapy options persistently result in permanent impairment brain functions. Due profound T cell depletion, T-cell function potent immunosuppressive factors, allogeneic hematopoietic...
Abstract Purpose Systemic amyloidosis represents a yet poorly characterized complex and multifaceted rare multisystem disease with high mortality. Clinical presentation, clinical course, treatment vary within across subtypes. Established biomarkers are predominantly non-specific. Diagnosis management of these patients require specifically tailored interdisciplinary structures. Well-characterized patient cohorts needed to optimize diagnostic tools options. Method The prospective cohort study...
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides unique therapeutic option patients ineligible CAR-T and bispecific antibody therapy, and/or progressing on anti-CD38 where bispecifics might be kept in reserve. Wider use drug can challenged by its distinct ocular side effect profile, including corneal microcysts keratopathy. While dose reduction has been most effective...
Cardiac metabolism remains altered for an extended period of time after myocardial infarction. Studies have shown fibroblasts from normal hearts express KATP channels in culture. It is unknown whether infarcted and these contribute to scar border zone electrophysiology. channel subunit expression levels were determined isolated (Fb), (sMI-Fb) remote (rMI-Fb) regions left anterior descending coronary artery (LAD) ligated rat hearts. Whole cell current density was with patch clamp. Action...
Abstract The multi‐agent therapy “VDT‐PACE” represents an established regimen in relapsed/refractory multiple myeloma (RRMM). Here, we report on our experience with a “modified VDT‐PACE” incorporating new generation anti‐MM agents daratumumab and carfilzomib (“Dara‐KDT‐P(A)CE”). We retrospectively analyzed 38 patients RRMM treated “Dara‐KDT‐P(A)CE”. median age was 62 (range 45–82) years, the were heavily pretreated of 5 2–12) prior lines therapy. Twenty‐one (55%) suffered from...
Abstract Measurement of minimal residual disease (MRD) by next‐generation flow cytometry (NGF) is an important tool to define deep responses in multiple myeloma (MM). However, little known about the value combining NGF with functional imaging and its role for MRD‐based consolidation strategies clinical routine. In present study, we report our experience investigating these issues 102 patients newly diagnosed ( n = 57) relapsed/refractory MM 45). Imaging was performed using either positron...
Light-chain amyloidosis (AL) is a rare multisystem disorder characterized by the deposition of misfolded amyloid fibrils derived from monoclonal immunoglobulin light chains in various organs. One most common organs involved AL heart, with 50-70% patients clinically symptomatic at diagnosis. We conducted multi-center, retrospective analysis 67 diagnosed between July 2012 and August 2022 European modification Mayo 2004 stage III cardiac AL. The important factors identified univariate Cox...
Optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m2) versus high-dose (≥36 in 103 pairs peripheral blood mononuclear cells from patients with relapsed/refractory (RR) multiple myeloma (MM). β5 activity was inhibited (median >50%) vivo by 20 mg/m2, whereas were co-inhibited only 36 56 respectively. Coinhibition (P=0.0001) (P=0.0005) differed significantly between carfilzomib....
Summary Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients treated with BCMA‐targeted T cells, and then divided them into three groups: (i) baseline (before leukapheresis), (ii) ≤day+30, (iii) >day+30 after therapy. evaluated laboratory data performed flow cytometry to determine the (CAR) subsets. Baseline...
Abstract Background Even in the era of novel immunotherapies for multiple myeloma (MM), treatment late‐stage relapsed/refractory (RR) patients remains challenging. The aim our study was to analyze efficacy and safety five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone, daratumumab (“Pom‐PAD‐Dara”) RRMM. Methods We retrospectively analyzed data 56 with RRMM who received Pom‐PAD‐Dara between September 2016 May 2019. Results Patients were heavily pretreated a median four...
Abstract We herein report the case of a 73‐year‐old male patient who was diagnosed with leukemic non‐nodal MCL. This had received six cycles bendamustine, which resulted in transient remission, and second‐line therapy ibrutinib, unfortunately failed to induce remission. started treatment single‐agent obinutuzumab at dose 20 mg on day 1, 50 2‐4, 330 5, 1000 6. The laboratory analysis showed rapid decrease leukocyte count. Four weeks later, we repeated q4w venetoclax 400 qd, could be increased...
Patients suffering from aggressive systemic peripheral lymphoma with primary central nervous system involvement (PCL) are a rare and sparsely investigated population. Recommended treatment regimens include combination of intrathecal chemotherapy as well whole brain radiotherapy while offering relatively poor survival.We conducted single-center retrospective study that analyzed safety outcome 4 + cycles Rituximab (R)-CHOP R-high-dose Methotrexate (HD-MTX) for newly diagnosed,...
CAR-T-Zell-Therapien (CAR chimärer Antigenrezeptor) stellen eine moderne Säule der Immuntherapie dar und füllen Lücke in Therapie rezidivierter bzw. refraktärer maligner B‑Zell- Plasmazellerkrankungen mit beeindruckenden Ansprechraten. So wird von den pharmazeutischen Herstellern die Produktionskapazität für CAR-T-Zell-Produkte aktuell gesteigert, um wachsenden Bedarf hohe Nachfrage zu decken. Die dennoch auftretenden Rezidive nach initial erfolgreicher noch mangelnde Wirksamkeit gegen...